hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-10-04 and is reviewed periodically as new material appears.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
==== Cheese ==== Louis de Jaucourt, in the Encyclopédie ou Dictionnaire raisonné des sciences, des arts et des métiers, cites a German who invented a way to make three cheeses, from large potatoes boiled in their skins, then peeled and ground with a spoon before being mixed with curdled milk; the cheeses obtained acquire more quality and finesse as they age. The Encyclopédie Méthodique, which includes this information, specifies the proportions according to which the cheese is intended for the poor (five pounds of vegetables for one pound of curd), for everyone (four pounds for two pounds of curd), or for the best tables (two pounds for four pounds of milk); by adding cream, large cheeses like those of Holland are made. She says that sheep's or goat's milk gives better results than cow's milk.
=== Recombinant human growth hormone (HGH, somatotropin) === Human growth hormone is administered to patients whose pituitary glands generate insufficient quantities to support normal growth and development. Before recombinant HGH became available, HGH for therapeutic use was obtained from pituitary glands of cadavers. This unsafe practice led to some patients developing Creutzfeldt–Jakob disease. Recombinant HGH eliminated this problem, and is now used therapeutically. It has also been misused as a performance-enhancing drug by athletes and others.
Ceruloplasmin (or caeruloplasmin) is a ferroxidase enzyme that in humans is encoded by the CP gene. Ceruloplasmin is the major copper-carrying protein in the blood, and in addition plays a role in iron metabolism. It was first described in 1948. Another protein, hephaestin, is noted for its homology to ceruloplasmin, and also participates in iron and probably copper metabolism.
Sources: en.wikipedia.org
== Biography == David Colin Sherrington was born at Webster Street, Litherland, Liverpool on 5 March 1945, the second child of Alfred George Sherrington, a dock labourer, and Lucy Gladys Sherrington, née Pyke. He attended two primary/junior schools before passing the eleven-plus exam, enabling him to go to Waterloo Grammar School. Crosby. His A-Level results were good enough for him to by-pass the first year of the chemistry degree course at the University of Liverpool and enter the second year in 1963. He graduated first-class in 1966. Sherrington stayed at Liverpool for his PhD, under Anthony Ledwith, and then continued as a research assistant in the same department so that he could help his recently widowed mother. In 1971 he applied for two fellowships: at Heriot-Watt University and at the University of Strathclyde. He was successful with the second, and took up a post in Alastair M. North’s department of pure and applied chemistry. Before moving north, David Sherrington married Valerie Vinnicombe at County Road Methodist Church, Walton in June 1972. They had met at the university tennis club, where she was secretary and he was trying to lose weight. By 1975 his researches in Scotland had become focused on polymer-supported reactions. In 1984 Sherrington accepted a three-year contract at Unilever’s Port Sunlight laboratory under its research director Sir Geoffrey Allen, FRS. His job was to build and lead the Polymer Science Area. He worked in fields that had practical value – always his wish – such as biodegradable polymers and molecular imprinting.
dihydrodipicolinate + H2O Once dihydrodipicolinate is synthesized, it can continue down the metabolic pathway leading to the synthesis of lysine. Other than the lysine biosynthetic pathway, L-aspartate-4-semialdehyde can also undergo a reversible reaction catalyzed by the enzyme homoserine dehydrogenase. This reaction, which turns L-aspartate-4-semialdehyde into homoserine is shown below:
The third case studied here is alpha-methylfentanyl. This group contains a substitution similar to the 3-methylfentanyl that was examined in the previous example on the previous image in this series (Fentanyl Synthesis p4.png), but it is on the phenethyl chain as opposed to being implanted on the piperidine ring. We then mark the two stereocenters, one on the C-4 carbon just as on fentanyl itself, and the other on the C-α (alpha carbon). To analogize these stereocenters we chose N-(1-hydroxyethyl)-4-hydroxypiperidine. When we draw out all potential stereoisomers, we see that the C-4 stereocenter is super-imposable, eliminating it as a true stereocenter. This leaves only 2 R/S assignments that follow the orientation of the stereocenter at the C-α (alpha carbon) position for the real α-methylfentanyl. These are labeled 7S and 7R, a reflection of the stereocenter in the piperidine derivative we used being at C-7 position. It is interesting that the C-4 stereocenter, which has no chiral activity in fentanyl (1st example), activiates it in 3-methylfentanyl with an on-the-ring addition, and loses it again in α-methylfentanyl with an off-the-ring addition. The fourth case studied here is ohmfentanyl. Ohmfentanyl has three potential stereocenters, which are best analogized by another piperidine derivative: N-(1-hydroxyethyl)-3-methyl-4-hydroxypiperidine. This uses a similar structure to analogize the three potential stereocenters in ohmfentanyl, namely the 4-C, the 3-C, and the β-C (beta carbon). These three stereocenters are analogized in the C-4, C-3, and C-7 respectively.
Sources: en.wikipedia.org
=== Piezoelectric effect === Density functional theory simulations predict that depositing certain adatoms on graphene can render it piezoelectrically responsive to an electric field applied in the out-of-plane direction. This type of locally engineered piezoelectricity is similar in magnitude to that of bulk piezoelectric materials and makes graphene a candidate for control and sensing in nanoscale devices.
Israel–Hezbollah conflict (2023–present): The Ministry of Defence announces that 700 British troops will be deployed to Cyprus in anticipation of an evacuation of British citizens from Lebanon. Starmer advises British nationals in Lebanon to "leave immediately" as tension between Hezbollah and Israel increases. 25 September – Petrol prices fall to their lowest level in three years, with the average price for a litre of unleaded costing about £1.35. 27 September Lexi Secker, a transgender woman who raped a woman on a night out prior to identifying as a woman, is jailed for six and a half years with the sentence to be served in a male prison. Two 13-year-old boys are detained for at least eight and a half years for the 2023 murder of Shawn Seesahai in Wolverhampton, carried out using a machete when they were 12. They are the youngest killers to be sentenced since the murder of James Bulger in 1993. Sir Brian May resigns as vice president of the Royal Society for the Prevention of Cruelty to Animals (RSPCA) over what he describes as "damning evidence" of animal welfare failings related to its food certification label. 28 September – Labour MP Rosie Duffield quits the party over what she describes as leader Keir Starmer's "cruel" policies and "staggering hypocrisy" over his acceptance of gifts. In her resignation letter to Starmer she says, "The sleaze, nepotism and apparent avarice are off the scale.
== Diagnosis == The only reliable way to determine whether a soft-tissue tumor is benign or malignant is through a biopsy. The two methods for acquisition of tumor tissue for cytopathological analysis are:
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.